[go: up one dir, main page]

TR200101233T2 - Endothelin antagonists. - Google Patents

Endothelin antagonists.

Info

Publication number
TR200101233T2
TR200101233T2 TR2001/01233T TR200101233T TR200101233T2 TR 200101233 T2 TR200101233 T2 TR 200101233T2 TR 2001/01233 T TR2001/01233 T TR 2001/01233T TR 200101233 T TR200101233 T TR 200101233T TR 200101233 T2 TR200101233 T2 TR 200101233T2
Authority
TR
Turkey
Prior art keywords
endothelin antagonists
antagonizing
endothelium
prepare
preparing
Prior art date
Application number
TR2001/01233T
Other languages
Turkish (tr)
Inventor
Winn Martin
A. Boyd Steven
W. Hutchins Charles
Jae Hwan-Soo
S. Tasker Andrew
W. Von Geldern Thomas
A. Kester Jeffrey
K. Sorensen Bryan
G. Szczepankiewicz Bruce
J. Henry Kenneth
Liu Gany
J. Wittenberger Steven
A. King Steven
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/905,913 external-priority patent/US6162927A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of TR200101233T2 publication Critical patent/TR200101233T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Bir formül (I) bilesigi veya farmasötik olarak kabul edilebilir bir tuzu açiklanmaktadir; ayrica bunlari hazirlamak için islemler ve bunlari hazirlamak için kullanilan ara maddelerin yani sira endotelini antagonize etmek için bir yöntem açiklanmaktadir.A compound of formula (I) or a pharmaceutically acceptable salt is disclosed; Also described is a process for antagonizing the endothelium as well as the processes for preparing them and the intermediates used to prepare them.

TR2001/01233T 1997-08-04 1998-07-27 Endothelin antagonists. TR200101233T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/905,913 US6162927A (en) 1994-08-19 1997-08-04 Endothelin antagonists
US4895598A 1998-03-27 1998-03-27

Publications (1)

Publication Number Publication Date
TR200101233T2 true TR200101233T2 (en) 2002-06-21

Family

ID=26726720

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2000/00993T TR200000993T2 (en) 1997-08-04 1998-07-27 Endothelin antagonists.
TR2005/01137T TR200501137T2 (en) 1997-08-04 1998-07-27 Endothelin antagonists.
TR2001/01233T TR200101233T2 (en) 1997-08-04 1998-07-27 Endothelin antagonists.
TR2001/01234T TR200101234T2 (en) 1997-08-04 1998-07-27 Endothelin antagonists.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TR2000/00993T TR200000993T2 (en) 1997-08-04 1998-07-27 Endothelin antagonists.
TR2005/01137T TR200501137T2 (en) 1997-08-04 1998-07-27 Endothelin antagonists.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/01234T TR200101234T2 (en) 1997-08-04 1998-07-27 Endothelin antagonists.

Country Status (16)

Country Link
EP (1) EP1003740A2 (en)
JP (1) JP2001512119A (en)
CN (1) CN1301264A (en)
AU (1) AU748469B2 (en)
BG (1) BG104216A (en)
BR (1) BR9815296A (en)
CA (1) CA2297894A1 (en)
HU (1) HUP0003484A3 (en)
IL (1) IL134175A0 (en)
NO (1) NO20000542L (en)
NZ (1) NZ502395A (en)
PL (1) PL342500A1 (en)
SK (1) SK1452000A3 (en)
TR (4) TR200000993T2 (en)
TW (1) TW552260B (en)
WO (1) WO1999006397A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337230A1 (en) * 1998-07-15 2000-01-27 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
EP1379238A1 (en) * 2001-04-11 2004-01-14 Abbott Laboratories Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
FR2874015B1 (en) * 2004-08-05 2006-09-15 Sanofi Synthelabo N- (1H-INDOLYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2880625B1 (en) * 2005-01-07 2007-03-09 Sanofi Aventis Sa N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2007034406A1 (en) * 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (en) 2010-06-04 2016-09-05 Amgen Inc Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
EP2970237B1 (en) 2013-03-14 2017-09-27 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (en) 2013-06-10 2017-06-16 Amgen Inc Processes of Making and Crystalline Forms of a MDM2 Inhibitor
CN104262329A (en) * 2014-10-22 2015-01-07 南京友杰医药科技有限公司 Preparation method for anti-form atrasentan
WO2023030470A1 (en) * 2021-09-03 2023-03-09 深圳信立泰药业股份有限公司 Endothelin a (eta) receptor antagonist compound, preparation method therefor and medical use thereof
JP2025524934A (en) * 2022-07-25 2025-08-01 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド Salts of endothelin A (ETA) receptor antagonist compounds, their preparation method and pharmaceutical use
CN117447453B (en) * 2022-07-25 2025-09-30 深圳信立泰药业股份有限公司 A pharmaceutically acceptable salt crystal form of an endothelin A (ETA) receptor antagonist compound and a preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
ATE219077T1 (en) * 1994-08-19 2002-06-15 Abbott Lab ENDOTHELIN ANTAGONIST
IL125453A0 (en) * 1996-02-13 1999-03-12 Abbott Lab 4-(Benzo-1,3-dioxylyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
US5618949A (en) * 1996-07-12 1997-04-08 Abbott Laboratories Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds

Also Published As

Publication number Publication date
WO1999006397A2 (en) 1999-02-11
HUP0003484A3 (en) 2002-02-28
TR200000993T2 (en) 2000-12-21
TR200101234T2 (en) 2002-06-21
BR9815296A (en) 2001-11-20
NO20000542D0 (en) 2000-02-02
TR200501137T2 (en) 2005-12-21
WO1999006397A3 (en) 1999-12-09
AU748469B2 (en) 2002-06-06
JP2001512119A (en) 2001-08-21
TW552260B (en) 2003-09-11
NZ502395A (en) 2002-08-28
SK1452000A3 (en) 2001-05-10
EP1003740A2 (en) 2000-05-31
CA2297894A1 (en) 1999-02-11
NO20000542L (en) 2000-04-04
BG104216A (en) 2000-12-29
CN1301264A (en) 2001-06-27
HUP0003484A2 (en) 2002-01-28
PL342500A1 (en) 2001-06-04
AU8592198A (en) 1999-02-22
IL134175A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
TR200101233T2 (en) Endothelin antagonists.
ATE297203T1 (en) ANTITHRBOTIC AGENTS
IL133627A0 (en) Antithrombotic agents
DE69931393D1 (en) ANTITHROMBOTIC AMIDE
DE69709938D1 (en) N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES
BG105457A (en) Method for the preparation of citalopram
IL143545A0 (en) Thrombin inhibitors
ATE219077T1 (en) ENDOTHELIN ANTAGONIST
MXPA02003977A (en) INHIBITORS OF agr;L.
ES8801245A1 (en) A PROCEDURE FOR PREPARING PIPERIDINE DERIVATIVES
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
MY103214A (en) Antihypercholesterolemic tetrazole compounds
EP1019047A4 (en) Antithrombotic agents
ES8700242A1 (en) Chemical compounds.
EP1027051A4 (en) Antithrombotic agents
NO996244L (en) Pyrrolidinecarboxylic acid derivatives as endothelin antagonists
IL156768A0 (en) Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
NO954769D0 (en) 3- (indol-3-yl) propenoic acid derivatives as NMDA antagonists
BR9810031A (en) Pyrrolidine carboxylic acid derivatives as endothelin antagonists
MX9701220A (en) Endothelin antagonists.
DE3855824D1 (en) Anti-plasmin depressant
EA200100163A1 (en) NEW DERIVATIVES 6-DEOXIERITROMYCIN, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL MEANS
DE69824410D1 (en) Antithrombosemittel